Baltimore Vaccine Plant Had Prior FDA Violations

The transcript discusses prior FDA violations at the Emergent Bio Solutions plant, including inadequate employee training and improper record-keeping. Despite these issues, the plant was selected for Operation Warp Speed, receiving significant funding. A recent mix-up at the plant affected up to 15 million doses of Johnson & Johnson and AstraZeneca COVID-19 vaccines.

What was the main issue reported by the FDA regarding the Johnson & Johnson COVID-19 vaccines?

• Lack of funding for vaccine production

• Contamination of vaccine doses

• Delayed vaccine distribution

• Prior FDA violations at the manufacturing plant

What specific problem did the FDA find at the Emergent BioSolutions plant?

• The plant was understaffed

• Vaccines were not stored at the correct temperature

• Employees were not properly trained

• There was a shortage of raw materials

What was one of the issues with record-keeping at the plant?

• Records were stored digitally

• Records were written in a foreign language

• Records were lost in a fire

• Records were not properly secured

What significant event occurred two months after the FDA inspection?

• The plant received a new management team

• The plant was shut down

• The plant was relocated

• The plant was selected for Operation Warp Speed

How many doses were affected by the recent mix-up at the plant?

• 20 million doses

• 15 million doses

• 10 million doses

• 5 million doses